Protection conferred by typhoid fever against recurrent typhoid fever in urban Kolkata.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
08
2019
accepted:
27
06
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
22
9
2020
Statut:
epublish
Résumé
We evaluated the protection conferred by a first documented visit for clinical care of typhoid fever against recurrent typhoid fever prompting a visit. This study takes advantage of multi-year follow-up of a population with endemic typhoid participating in a cluster-randomized control trial of Vi capsular polysaccharide typhoid vaccine in Kolkata, India. A population of 70,566 individuals, of whom 37,673 were vaccinated with one dose of either Vi vaccine or a control (Hepatitis A) vaccine, were observed for four years. Surveillance detected 315 first typhoid visits, among whom 4 developed subsequent typhoid, 3 due to reinfection, defined using genomic criteria and corresponding to -124% (95% CI: -599, 28) protection by the initial illness. Point estimates of protection conferred by an initial illness were negative or negligible in both vaccinated and non-vaccinated subjects, though confidence intervals around the point estimates were wide. These data provide little support for a protective immunizing effect of clinically treated typhoid illness, though modest levels of protection cannot be excluded.
Identifiants
pubmed: 32804950
doi: 10.1371/journal.pntd.0008530
pii: PNTD-D-19-01180
pmc: PMC7430703
doi:
Substances chimiques
Antibodies, Bacterial
0
Typhoid-Paratyphoid Vaccines
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008530Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Transl Med. 2016 Mar 01;14:62
pubmed: 26928826
PLoS Negl Trop Dis. 2014 Jan 09;8(1):e2642
pubmed: 24416466
J Hyg (Lond). 1957 Sep;55(3):334-43
pubmed: 13475778
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
PLoS Pathog. 2014 Jul 03;10(7):e1004207
pubmed: 24992093
J Infect Dis. 2011 Sep 15;204(6):912-8
pubmed: 21849288
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):
pubmed: 25964454
Bull World Health Organ. 1971;44(5):667-72
pubmed: 5316750
Nat Commun. 2018 Nov 30;9(1):5094
pubmed: 30504848
PLoS Negl Trop Dis. 2012 Jan;6(1):e1490
pubmed: 22303491
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
Nat Genet. 2015 Jun;47(6):632-9
pubmed: 25961941
N Engl J Med. 2011 Jul 28;365(4):337-46
pubmed: 21793745
N Engl J Med. 2009 Jul 23;361(4):335-44
pubmed: 19625715
J Hyg (Lond). 1953 Jun;51(2):260-7
pubmed: 13069708
Clin Infect Dis. 2015 Aug 1;61(3):393-402
pubmed: 25870324
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
EBioMedicine. 2018 May;31:92-109
pubmed: 29735417
PLoS One. 2013 Sep 10;8(9):e74097
pubmed: 24040177
Clin Infect Dis. 2012 Apr;54(7):955-63
pubmed: 22318974
PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006408
pubmed: 29684021
BMJ. 2006 Jul 8;333(7558):78-82
pubmed: 16825230
J Infect Dis. 2001 Jan 15;183(2):261-268
pubmed: 11120931
PLoS Pathog. 2015 May 22;11(5):e1004914
pubmed: 26001081
N Engl J Med. 2019 Dec 5;381(23):2209-2218
pubmed: 31800986